Early inhaled budesonide in extremely preterm infants decreases long-term respiratory morbidity

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F20%3A10411481" target="_blank" >RIV/00216208:11110/20:10411481 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/20:10411481

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=pKCyuM0nhO" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=pKCyuM0nhO</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/ppul.24704" target="_blank" >10.1002/ppul.24704</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Early inhaled budesonide in extremely preterm infants decreases long-term respiratory morbidity

Popis výsledku v původním jazyce

Background: There is no strict correlation between early bronchopulmonary dysplasia and long-term respiratory disease. Early inhaled corticosteroids seem to reduce the incidence of bronchopulmonary dysplasia, but the long-term outcome remains unknown. Research Question: The aim of this study was to evaluate the effect of early inhaled corticosteroids on chronic respiratory morbidity. Methods: Fifty-nine survivors from the Prague cohort included in Neonatal European Study of Inhaled Steroids underwent further follow-up comprising of respiratory morbidity monitoring during the first 2 years of life followed by objective lung function testing performed at the age of 5.9 years (range 5-7 years). Both outcomes were pursued and finalized before the unblinding of budesonide subgroups. Results: Fifty randomized (budesonide vs placebo group, 56% vs 44%) survivors were included in the study. Spirometry was successfully performed in 48 children. No statistically significant differences were found in the lung function test (forced expiratory flow [FEF] - FEF75, FEF50, FEF25, and FEF25-75; FEV1, forced vital capacity [FVC], FEV1/FVC) although mild trend to the improvement of expiratory flow pattern was observed in the budesonide group (median z -score of FEV1/FVC -0.376 vs -0.983, P = .13; median z -score of FEF25-75 -1.004 vs -1.458, P = .13; median z -score of FEF75 -0.527 vs -0.996, P = .17). Children assigned to budesonide had a significantly lower rate of symptoms of chronic lung disease (34.6% vs 68.2%; P = .04) than children assigned to placebo. Interpretation: Our study suggests that early inhaled budesonide was associated with the trend to the improvement of functional lung parameters and with a lower rate of symptoms of chronic lung disease within the first 2 years of life.

Název v anglickém jazyce

Early inhaled budesonide in extremely preterm infants decreases long-term respiratory morbidity

Popis výsledku anglicky

Background: There is no strict correlation between early bronchopulmonary dysplasia and long-term respiratory disease. Early inhaled corticosteroids seem to reduce the incidence of bronchopulmonary dysplasia, but the long-term outcome remains unknown. Research Question: The aim of this study was to evaluate the effect of early inhaled corticosteroids on chronic respiratory morbidity. Methods: Fifty-nine survivors from the Prague cohort included in Neonatal European Study of Inhaled Steroids underwent further follow-up comprising of respiratory morbidity monitoring during the first 2 years of life followed by objective lung function testing performed at the age of 5.9 years (range 5-7 years). Both outcomes were pursued and finalized before the unblinding of budesonide subgroups. Results: Fifty randomized (budesonide vs placebo group, 56% vs 44%) survivors were included in the study. Spirometry was successfully performed in 48 children. No statistically significant differences were found in the lung function test (forced expiratory flow [FEF] - FEF75, FEF50, FEF25, and FEF25-75; FEV1, forced vital capacity [FVC], FEV1/FVC) although mild trend to the improvement of expiratory flow pattern was observed in the budesonide group (median z -score of FEV1/FVC -0.376 vs -0.983, P = .13; median z -score of FEF25-75 -1.004 vs -1.458, P = .13; median z -score of FEF75 -0.527 vs -0.996, P = .17). Children assigned to budesonide had a significantly lower rate of symptoms of chronic lung disease (34.6% vs 68.2%; P = .04) than children assigned to placebo. Interpretation: Our study suggests that early inhaled budesonide was associated with the trend to the improvement of functional lung parameters and with a lower rate of symptoms of chronic lung disease within the first 2 years of life.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30209 - Paediatrics

Projekt

—

Návaznosti

O - Projekt operacniho programu

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Pediatric Pulmonology

ISSN

8755-6863

e-ISSN

—

Svazek periodika

55

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

1124-1130

Kód UT WoS článku

000517352700001

EID výsledku v databázi Scopus

2-s2.0-85081016882